2017美国癌症报告(英文)

Cancer Statistics, 2017Rebecca L. Siegel, MPH1; Kimberly D. Miller, MPH2; Ahmedin Jemal, DVM, PhD3Abstract:Each year, the American Cancer Society estimates the numbers of new can-cer cases and deaths that will occur in the United States in the current year and com-piles the most recent data on cancer incidence, mortality, and survival. Incidence datawere collected by the Surveillance, Epidemiology, and End Results Program; the NationalProgram of Cancer Registries; and the North American Association of Central CancerRegistries. Mortality data were collected by the National Center for Health Statistics. In2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occurin the United States. For all sites combined, the cancer incidence rate is 20% higher inmen than in women, while the cancer death rate is 40% higher. However, sex disparitiesvary by cancer type. For example, thyroid cancer incidence rates are 3-fold higher inwomen than in men (21 vs 7 per 100,000 population), despite equivalent death rates(0.5 per 100,000 population), largely reflecting sex differences in the “epidemic of diag-nosis.” Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while thecancer death rate (2005-2014) declined by about 1.5% annually in both men and women.From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approxi-mately 2,143,200 fewer cancer deaths than would have been expected if death rateshad remained at their peak. Although the cancer death rate was 15% higher in blacksthan in whites in 2014, increasing access to care as a result of the Patient Protectionand Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, theproportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics(31% to 16%). Gains in coverage for traditionally underserved Americans will facilitate thebroader application of existing cancer control knowledge across every segment of thepopulation. CA Cancer J Clin 2017;67:7–30. VC 2017 American Cancer Society.Keywords: cancer cases, cancer statistics, death rates, incidence, mortalityIntroductionCancer is a major public health problem worldwide and is the second leading cause ofdeath in the United States. In this article, we provide the expected numbers of newcancer cases and deaths in 2017 in the United States nationally and for each state, aswell as a comprehensive overview of cancer incidence, mortality, and survival rates andtrends using population-based data. The most current cancer data are availablethrough 2013 for incidence and through 2014 for mortality. We also estimate the totalnumber of deaths averted as a result of the continual decline in cancer death rates sincethe early 1990s. In addition, we present the actual number of deaths reported in 2014by age for the 10 leading causes of death and for the 5 leading causes of cancer death.Materials

立即下载
医药生物
2017-08-14
美国癌症协会
24页
1.54M
收藏
分享

[美国癌症协会]:2017美国癌症报告(英文),点击即可下载。报告格式为PDF,大小1.54M,页数24页,欢迎下载。

本报告共24页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共24页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
图 44、2016 年全球抗艾滋病畅销药物 Top10
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
表 1、全球 2017 最畅销药物前十名 排名 药品名 销售额(亿美元) 产品由来
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
图 41、2000-2016 年辉瑞营收及增速 图 42、2000-2016 年辉瑞净利润及增速
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
图 40、立普妥历年销售额(亿美元)及增速
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
图 39、2000 年以来辉瑞股价走势
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
图 38、2000 年以来辉瑞主要并购案例梳理
医药生物
2018-08-04
来源:医药生物行业深度报告:品种引进大潮起,授权引进模式方兴未艾
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起